SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue, signaling continued momentum for its SSi Mantra surgical robotic platform. The company generated $13.9 million in revenue for the quarter, a 39.4% increase from $10.0 million in the same period last year. Gross profit rose 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter (https://nnw.fm/zxrT1).
For the first half of the year, revenue reached $25.0 million, a 65.6% increase from $15.1 million in the first half of 2025. Gross profit increased 77.5% to $12.4 million, indicating improved operational efficiency despite the quarterly margin dip. The company's installations of SSi Mantra systems rose 30.4% to 30 systems during the quarter, bringing the installed base to 224 systems across 12 countries. Cumulative surgeries performed reached 12,272, reflecting growing clinical adoption.
The financial results underscore the commercial traction of SSi Mantra as a competitive alternative in the surgical robotics market. With an expanding installed base and increasing surgical volume, SS Innovations is building a recurring revenue stream from service and instrument sales, which could provide more stable growth beyond initial system sales.
Key catalysts lie ahead in the regulatory pipeline. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these milestones would open access to the U.S. and European markets, which are among the largest for surgical robotics. Analysts view these approvals as critical for scaling the platform and challenging established players like Intuitive Surgical.
In addition to regulatory progress, SS Innovations is advancing telesurgery capabilities, which extend the clinical profile of SSi Mantra. Telesurgery allows surgeons to operate remotely, potentially expanding access to specialized care in underserved regions. While telesurgery is still emerging, it differentiates SSi Mantra and could drive future demand.
System installations remain the primary driver of commercial growth, and the company's ability to increase installations by 30% year-over-year demonstrates strong demand in its current markets. The company's focus on cost-effective robotic surgery could appeal to hospitals seeking to reduce procedural costs while improving patient outcomes.
Investors will watch for continued execution on regulatory timelines and expansion into new geographies. With a robust installed base and growing procedural volume, SS Innovations is positioning itself for sustained growth. The company's performance in the first half of 2026 sets a solid foundation for the remainder of the year, but the upcoming regulatory decisions will likely be pivotal in determining the long-term trajectory.
